Natco Pharma Limited — Important, 12-11-2024: Financial Result Updates

NATCO Pharma Limited has announced a board meeting to discuss its financial results. For Q2 FY2025, the company reported consolidated total revenue of ₹1,434.9 crore, representing a robust growth of 35.3% year-over-year compared to ₹1,060.8 crore in Q2 FY2024. Net profit showed an impressive increase of 83%, reaching ₹676.5 crore, up from ₹369.0 crore.

Significant drivers of this growth include strength in export formulations and a stable domestic pharmaceutical business. Operationally, the company's key segments were led by Formulations Export, which contributed ₹1,211.3 crore, while Active Pharmaceutical Ingredients (API) saw revenues of ₹49.6 crore.

Operational costs were well-managed, indicating efficient cost control measures. The balance sheet remains solid, suggesting a healthy financial position with sufficient cash flow. The Board has declared a second interim dividend of ₹1.50 per equity share. Given the strong financial performance, the sentiment remains positive; thus, this could be viewed as an opportunity to consider a buy.